CION Ameerpet
Cutaneous T-cell lymphoma is a skin lymphoma in which abnormal T-cells settle in the skin. Its subtype and stage — from early mycosis fungoides to Sézary syndrome — shape the plan. This guide explains it clearly and how CION's lymphoma team cares for it.
Cutaneous T-cell lymphoma (CTCL) is a group of skin lymphomas in which malignant T-lymphocytes — a type of white blood cell — collect mainly in the skin rather than in the lymph nodes or bloodstream. It is a form of non-Hodgkin T-cell lymphoma, but unlike most lymphomas it begins in and stays largely confined to the skin, often for many years.
The most common subtype by far is mycosis fungoides, which usually runs a slow, indolent course. Because it starts as flat, itchy patches, mycosis fungoides is frequently mistaken for eczema, psoriasis or a persistent fungal rash long before the diagnosis is confirmed. A more advanced, blood-involving variant is Sézary syndrome. Getting the exact subtype and stage right — through a skin biopsy and pathology — is what shapes the whole treatment plan and the outlook.
This guide walks through what skin lymphoma looks like, how it is diagnosed, its subtypes, and how it is treated. For the full picture of lymphoma care, see our Lymphoma hub and our Lymphoma Treatment in Hyderabad page.
Mycosis fungoides is the most common type of cutaneous T-cell lymphoma, yet it is a rare disease overall — and because its early patches closely resemble eczema or psoriasis, the diagnosis can take years and several skin biopsies to confirm. This is why a persistent, itchy rash that does not clear with standard creams deserves a specialist dermatology and pathology review. (Source: NCCN and ESMO clinical practice guidelines on primary cutaneous lymphomas.)
Mycosis fungoides evolves slowly, and its earliest signs are easy to dismiss as an ordinary rash. Knowing what to look for — and when a rash has gone on too long — helps get to the right diagnosis sooner.
Most persistent rashes are not lymphoma. But a rash that is new, persistent and resistant to routine treatment for months should be reviewed and, if needed, biopsied. Speak to a CION specialist if you have these signs or a confirmed skin lymphoma.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Just diagnosed with cutaneous T-cell lymphoma, want to understand your subtype and stage, or need a second opinion before treatment? CION's lymphoma team is here.
Cutaneous T-cell lymphoma is not a single disease but a family of skin lymphomas that behave very differently. Knowing the exact subtype — confirmed on a skin biopsy — is what lets the team tailor treatment precisely.
| Subtype | Behaviour | Key features |
|---|---|---|
| Mycosis fungoides | Usually indolent (slow-growing) | Most common CTCL; evolves through patch, plaque and — in a minority — tumour stages over years |
| Sézary syndrome | More aggressive; leukaemic | Widespread red skin (erythroderma), enlarged nodes and malignant T-cells circulating in the blood |
| Primary cutaneous anaplastic large cell lymphoma | Often indolent when skin-limited | CD30-positive; presents as one or a few raised skin nodules |
| Other rare CTCL variants | Variable | Assessed individually against WHO classification and pathology |
Behaviour and outcomes vary by individual. Subtype and staging follow the WHO classification and NCCN/ESMO guidance. Related nodal T-cell subtypes such as peripheral T-cell lymphoma are distinct diseases that mainly involve lymph nodes rather than the skin.
Diagnosing cutaneous T-cell lymphoma — and pinning down its exact subtype and stage — takes a step-by-step pathway. CION delivers the biopsy, pathology, staging and review directly.
A skin biopsy is the cornerstone of diagnosis. Because early mycosis fungoides closely resembles inflammatory skin conditions, more than one biopsy over time is sometimes needed before the diagnosis is confirmed. The tissue is examined under the microscope and with immunohistochemistry for T-cell markers such as CD3, CD4 and CD30. These markers are testing concepts that help classify the tumour and, for some subtypes, guide targeted treatment.
T-cell receptor clonality testing can confirm that a single abnormal T-cell clone is present. If Sézary syndrome is suspected, a blood test looks for circulating Sézary cells, supported by flow cytometry to measure how many abnormal T-cells are in the bloodstream.
Staging assesses how much of the skin, lymph nodes, blood and internal organs are involved, using the TNMB system specific to CTCL. Imaging such as CT or PET-CT is used when internal or nodal involvement is a concern. Per NCCN and ESMO guidance, accurate staging is essential because early skin-limited disease and advanced disease are treated very differently. Every case is reviewed by CION's multidisciplinary tumour board before the plan is set.
In cutaneous T-cell lymphoma, stage is the single most powerful guide to treatment and outlook. Per NCCN and ESMO guidance, most people with early, skin-limited mycosis fungoides have an excellent long-term prognosis and can expect years of good disease control with skin-directed therapy alone — whereas advanced-stage disease and Sézary syndrome behave more aggressively and need systemic treatment. Figures vary by individual, which is why accurate staging on tissue and blood, not appearance alone, should guide every plan.
The treatment plan depends on the subtype, stage and how much skin and body is involved, and is set by CION's multidisciplinary tumour board. The aim in early disease is long-term control and quality of life. The main building blocks are:
For early, skin-limited mycosis fungoides, skin-directed therapy often controls the disease for years. This includes topical treatments and phototherapy (medical light therapy). These approaches treat the skin while sparing the rest of the body from systemic treatment, and are managed directly by CION's team.
Localised skin lymphoma often responds very well to radiation therapy. CION delivers precision IMRT directly, targeting individual plaques or tumours while sparing healthy tissue. When widespread skin treatment is needed, total-skin radiation is coordinated through accredited partner facilities.
More advanced or widespread disease may need systemic treatment. Depending on the subtype and markers, this can include antibody-based therapy directed at a marker such as CD30, other targeted agents, or chemotherapy — all delivered in-house by CION's medical oncology team. We describe therapy by class and mechanism only; your specialist will match the exact regimen to your diagnosis. For the full menu of options, see Lymphoma Treatment in Hyderabad.
For selected patients with aggressive or advanced disease, a stem-cell transplant may be considered — this is coordinated through accredited partner facilities, not delivered in-house. Throughout, CION manages supportive care, symptom relief and long-term monitoring, because CTCL is often a chronic condition that needs ongoing follow-up.
A cutaneous T-cell lymphoma diagnosis carries a lot of nuance, and a second opinion is especially valuable in a few situations:
CION offers a dedicated, free written second-opinion service, and you can also consult our best lymphoma doctors in Hyderabad at our lymphoma hospital in Hyderabad. You deserve a plan built around healing, not billing — with transparent costs explained up front. Request your free second opinion or call 18002028726.
Get a free written second opinion from CION's lymphoma tumour board — especially valuable if the subtype or stage of your cutaneous T-cell lymphoma is still uncertain.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Cutaneous T-cell lymphoma (CTCL) is a group of skin lymphomas in which malignant T-lymphocytes settle mainly in the skin rather than in lymph nodes or the bloodstream. It is a form of non-Hodgkin T-cell lymphoma that starts in and stays largely confined to the skin for long periods. The most common type is mycosis fungoides, which typically runs a slow, indolent course over years. Because it looks like eczema or psoriasis in its early stages, skin lymphoma is often mistaken for a common rash before the diagnosis is confirmed on a skin biopsy. Understanding the exact subtype guides the whole treatment plan — explore our lymphoma hub for the wider picture.
Both are cutaneous T-cell lymphomas, but they differ in how widely the disease has spread. Mycosis fungoides is the classic, slow-growing form that stays mainly in the skin, evolving through patch, plaque and — in a minority — tumour stages over many years. Sézary syndrome is a more advanced, leukaemic variant in which the same malignant T-cells circulate in the blood, causing widespread red, itchy skin (erythroderma), enlarged lymph nodes and characteristic Sézary cells on a blood film. In practice they sit on a spectrum. Sézary syndrome behaves more aggressively and needs systemic treatment sooner, whereas early mycosis fungoides is often managed with skin-directed therapy alone.
The earliest sign of mycosis fungoides is usually a persistent, itchy, scaly patch or slightly raised plaque on the skin — often on areas not exposed to the sun, such as the buttocks, hips, lower trunk or upper thighs. These patches can be dry, discoloured (lighter or darker than surrounding skin) and are frequently mistaken for eczema, psoriasis or a stubborn fungal rash. What sets skin lymphoma apart is that the patches persist or slowly grow over months to years and do not fully clear with standard creams or antifungal treatment. In later stages, thicker plaques or raised tumours may develop. A skin rash that has resisted routine treatment for months deserves a dermatology review and, if needed, a skin biopsy.
Diagnosis rests on a skin biopsy examined by a pathologist, supported by clinical assessment. Because early mycosis fungoides can mimic inflammatory skin conditions, more than one biopsy over time is sometimes needed before the diagnosis is confirmed. The tissue is studied under the microscope and with immunohistochemistry for T-cell markers such as CD3, CD4 and CD30, and T-cell receptor clonality testing may be used to confirm a single abnormal clone. If Sézary syndrome is suspected, a blood test looks for circulating Sézary cells and flow cytometry. Staging then assesses skin, lymph nodes, blood and internal organs, sometimes with a PET-CT or CT. CION performs biopsy, pathology and staging directly and reviews every case at a tumour board.
Treatment depends on the stage and how much of the skin and body is involved, and is set by a multidisciplinary tumour board. Early-stage disease is often controlled for years with skin-directed therapy — topical treatments, phototherapy (light therapy) and localised radiation. CION delivers precision radiation (IMRT) and skin-directed care directly. More advanced or widespread disease may need systemic treatment such as antibody-based therapy targeting markers like CD30, targeted agents or chemotherapy, all delivered in-house by our medical oncology team. Total-skin radiation and stem-cell transplant, when indicated, are coordinated through accredited partner facilities. For the full menu of options see Lymphoma Treatment in Hyderabad. We do not name specific drug regimens here — your specialist will match therapy to your subtype and stage.
For most people, early-stage mycosis fungoides is a chronic, manageable condition rather than an immediately life-threatening cancer. Many patients with early, skin-limited disease have a life expectancy close to that of the general population and live for decades with treatment that controls symptoms. Published series show that outlook depends strongly on stage: early-stage disease carries an excellent long-term prognosis, while advanced-stage disease and Sézary syndrome are more aggressive and harder to control. These figures vary by individual and by subtype, and should be interpreted per NCCN and ESMO guidance with your own specialist. The goal in early disease is long-term control and quality of life; a smaller number of patients progress and need more intensive, coordinated treatment.
In most people, mycosis fungoides stays confined to the skin for many years and never spreads internally. In a minority, and usually slowly, the disease can advance from flat patches to thicker plaques and raised tumours, and eventually involve lymph nodes, blood or internal organs. When malignant T-cells enter the bloodstream in large numbers, the condition overlaps with Sézary syndrome. This is why regular monitoring of the skin, lymph nodes and — when indicated — the blood is part of long-term care. Any rapid change, new lumps, or widespread reddening of the skin should prompt a prompt review. Related T-cell subtypes such as peripheral T-cell lymphoma and anaplastic large cell lymphoma behave differently and are assessed separately.
Browse our complete guide to lymphoma — symptoms, diagnosis, Hodgkin and non-Hodgkin subtypes, treatment, genetics, prognosis, survivorship and cost. Tap any topic to read more.